Vast Therapeutics, Inc.

Publicly observed

Morrisville, United States

Seen in a public record (e.g. a government grant database); not otherwise verified.

Details and provenance

Item	Value	Source	Status
Country	US	NIH RePORTER (opens in a new tab) 28 Sept 2026	Publicly observed
City / locality	Morrisville	NIH RePORTER (opens in a new tab) 28 Sept 2026	Publicly observed
Name	Vast Therapeutics, Inc.	NIH RePORTER (opens in a new tab) 28 Sept 2026	Publicly observed
UEI (U.S. federal entity ID)	CYDMYQAP1ZW7	NIH RePORTER (opens in a new tab) 28 Sept 2026	Publicly observed

Grant14 Sept 2026Publicly observed
NIH SBIR/STTR award: Inhaled Nitric-Oxide Releasing Prodrug to Treat Drug Resistant Klebsiella pneumoniae Infections
USD 1,000,000.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Grant11 Sept 2025Publicly observed
NIH SBIR/STTR award: Nebulized ALX1 as a Treatment for Difficult Non-tuberculous Mycobacterial Lung Infections
USD 950,129.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Grant11 Sept 2025Publicly observed
NIH SBIR/STTR award: Nebulized ALX1 as a Treatment for Difficult Non-tuberculous Mycobacterial Lung Infections
USD 1,000,000.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Grant20 Dec 2024Publicly observed
NIH SBIR/STTR award: Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients
USD 988,594.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Grant20 Dec 2024Publicly observed
NIH SBIR/STTR award: Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients
USD 1,000,000.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)

Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.